

**PBS 60 sec PROMO\_09.30\_ISI :US-ANK-250065-v1**

00:00:01:21 - 00:00:24:00

RICH

So when you look back in any innovation, whether it's putting man on the moon, whether it's the greatest discoveries of medicine, most people, they feel like it happens almost overnight. But what I'll let you know is that it's literally decades in the making. Understand there's a group of 700 people that have worked around the clock day and night, for years or decades to get to this point.

00:00:24:03 - 00:00:45:00

RICH

When we received the call to say that the FDA had approved Anktiva for non muscle invasive bladder cancer, obviously we were overjoyed.

PATRICK

It's probably the most exciting time, not only in my career, but to be at ImmunityBio. Because we have now the convergence of all technology. There's an ability to actually create a cancer vaccine so that we can treat the tumor, and it doesn't come back.

00:00:45:02 - 00:01:00:00

RICH

And that's what patients and families want, is to know that I'm cancer free, and I have every chance of being cancer free for the long term.

VOICEOVER

Immunity bio incorporated smart therapies for difficult diseases. To learn more, visit [Immunity bio.com](http://Immunity bio.com).

...

## Indication and Important Safety Information For Anktiva

### INDICATION AND USAGE

ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG)

for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC)

with carcinoma in situ (CIS) with or without papillary tumors.

### WARNINGS AND PRECAUTIONS

Risk of Metastatic Bladder Cancer with Delayed Cystectomy.

Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal.

If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

CONTRAINDICATIONS: None

### DOSAGE AND ADMINISTRATION

For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes.

Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

### USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

#### ADVERSE REACTIONS

The most common ( $\geq 15\%$ ) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria,

urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at [www.anktiva.com](http://www.anktiva.com).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit [www.FDA.gov/medwatch](http://www.FDA.gov/medwatch) or call 1-800-332-1088.

You may also contact ImmunityBio at 1-877-ANKTIVA (1-877-265-8482)